EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Treating metastatic extraocular retinoblastoma complicated with Langerhans cell histiocytosis

Marya Hameed, Fatima Siddiqui, Muhammad Khuzzaim Khan, Sindhura Tadisetty, Prasanna Kumar Gangishetti

GMS Ophthalmology Cases · 04.11.2025 · 15 (Doc10) · Doc10-Doc10

DOI: 10.3205/oc000258 ↗

Kurz gefasst

Fallbericht in der Zeitschrift GMS Ophthalmology Cases, erschienen am 04.11.2025. Verfasst von Marya Hameed und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Child Health, Karachi, Pakistan. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Retinoblastoma (Rb) and Langerhans cell histiocytosis (LCH) are rare and distinct diseases that can coexist in a patient. We present a case report of a 5-year-old male who was diagnosed with bilateral retinoblastoma and LCH involving the skull and spine.

Methods

The patient underwent a detailed clinical evaluation, including a complete ophthalmic examination, neuroimaging studies, and bone marrow biopsy. A genetic test confirmed the presence of the BRAF V600E mutation in the LCH lesion. Treatment with BRAF inhibitors was initiated for LCH, followed by chemotherapy and left eye enucleation for retinoblastoma. The patient was monitored closely during treatment and at follow-up visits.

Results

The patient responded well to therapy, with no evidence of disease recurrence at 12-month follow-up and the enucleated eye was replaced with a prosthesis. The BRAF inhibitor was found to be an effective therapeutic option for the patient with BRAF-positive LCH.

Conclusion

Our case highlights the importance of early diagnosis and prompt treatment in managing complex cases with coexisting retinoblastoma and LCH. Treatment with BRAF inhibitors could be a promising therapeutic option for patients with BRAF-positive LCH. Further studies are needed to evaluate the efficacy and safety of BRAF inhibitors in the treatment of LCH. The long-term outcome and potential late effects of combined therapy for coexisting retinoblastoma and LCH should also be monitored closely.

Schlagwörter

Stichwörter der Autor:innen

Langerhans cell histiocytosischemotherapyeye neoplasmslow visionretinoblastoma

Autor:innen und Institutionen

  • National Institute of Child Health, Karachi, Pakistan.
  • Dow University of Health Sciences, Karachi, Pakistan.
  • University of Kentucky, Lexington KY, USA.

Zitieren

APA

Hameed, M., Siddiqui, F., Khan, M. K., Tadisetty, S., & Gangishetti, P. K. (2025). Treating metastatic extraocular retinoblastoma complicated with Langerhans cell histiocytosis. GMS Ophthalmology Cases, 15(Doc10), Doc10-Doc10. https://doi.org/10.3205/oc000258

Vancouver

Hameed M, Siddiqui F, Khan MK, Tadisetty S, Gangishetti PK. Treating metastatic extraocular retinoblastoma complicated with Langerhans cell histiocytosis. GMS Ophthalmology Cases. 2025;15(Doc10):Doc10-Doc10. doi:10.3205/oc000258

BibTeX
@article{Hameed2025,
  author = {Hameed, Marya and Siddiqui, Fatima and Khan, Muhammad Khuzzaim and Tadisetty, Sindhura and Gangishetti, Prasanna Kumar},
  title = {Treating metastatic extraocular retinoblastoma complicated with Langerhans cell histiocytosis},
  journal = {GMS Ophthalmology Cases},
  year = {2025},
  volume = {15},
  number = {Doc10},
  pages = {Doc10--Doc10},
  doi = {10.3205/oc000258}
}
Kostenlos starten →